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A B S T R A C T
There is some recent evidence that cardiac ischemia/reperfusion (I/R) injury induces intestinal damage within
days, which contributes to adverse cardiovascular outcomes after myocardial infarction. However, it is not clear
whether remote gut injury has any detectable early signs, and whether different interventions aiming to reduce
cardiac damage are also effective at protecting the intestine. Previously, we found that chronic treatment with
rofecoxib, a selective inhibitor of cyclooxygenase-2 (COX-2), limited myocardial infarct size to a comparable
extent as cardiac ischemic preconditioning (IPC) in rats subjected to 30-min coronary artery occlusion and 120-
min reperfusion. In the present study, we aimed to analyse the early intestinal alterations caused by cardiac I/R
injury, with or without the above-mentioned infart size-limiting interventions. We found that cardiac I/R injury
induced histological changes in the small intestine within 2 h, which were accompanied by elevated tissue level
of COX-2 and showed positive correlation with the activity of matrix metalloproteinase-2 (MMP-2), but not of
MMP-9 in the plasma. All these changes were prevented by rofecoxib treatment. By contrast, cardiac IPC failed to
reduce intestinal injury and plasma MMP-2 activity, although it prevented the transient reduction in jejunal
blood flow in response to cardiac I/R. Our results demonstrate for the first time that rapid development of
intestinal damage follows cardiac I/R, and that two similarly effective infarct size-limiting interventions, rofe-
coxib treatment and cardiac IPC, have different impacts on cardiac I/R-induced gut injury. Furthermore, in-
testinal damage correlates with plasma MMP-2 activity, which may be a biomarker for its early diagnosis.
1. Introduction
Myocardial infarction (MI) is one of the leading causes of death
worldwide, and early reperfusion of the myocardium is the most ef-
fective treatment to reduce cardiac injury and infarct size [1]. Re-
perfusion of the ischemic myocardium, however, can paradoxically
induce further tissue damage, a phenomenon called ischemia/reperfu-
sion (I/R) injury, which has been described and characterized in nu-
merous organs. The pathogenesis of I/R injury involves common factors
in all tissues, including endothelial dysfunction, activation of leuko-
cytes, generation of reactive oxygen and nitrogen species (RONS) and
the release of cytokines and other mediators like matrix
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metalloproteinases (MMPs) [2]. MMPs are a family of zinc-containing
neutral endopeptidases, which, besides degrading components of the
extracellular matrix, also regulate the release or activation of cytokines,
chemokines, various growth factors and numerous other bioactive
molecules in a variety of physiological and pathophysiological condi-
tions [3]. Distinct types of MMPs, particularly MMP-2 and MMP-9, are
released rapidly upon I/R and contribute to tissue injury [4,5]. In ad-
dition, upon the reperfusion of ischemic tissues all these mediators [2]
including MMPs [6,7] are released into the bloodstream and delivered
to distant organs, where they may induce damage as well (remote organ
injury).
The intestinal mucosa is particularly vulnerable to the deleterious
effects of local I/R [8]. Intestinal injury and impaired mucosal barrier
integrity enable luminal aggressive factors like bacteria and bile acids
to enter the gut tissue and trigger an inflammatory response at both
local and remote sites. On the other hand, intestinal damage may be an
early consequence of I/R injury of distant organs as well. Histological
alterations of the gut with increased permeability have been observed
as early as 2 h after reperfusion of the ischemic limbs [9,10]. Inter-
estingly, much attention have been paid to remote gut injury following
I/R of the limb or kidney [9–12], but little is known about the intestinal
effects of cardiac reperfusion after MI. In an animal model of MI in-
testinal barrier was impaired 17 days after reperfusion [13]. In a more
recent study increased intestinal permeability was reported on days 1–7
of symptom onset in ST-segment elevation MI patients undergoing
primary percutaneous coronary intervention. Plasma levels of gut-de-
rived bacterial products correlated with the severity of systemic in-
flammation and predicted adverse cardiovascular events, suggesting
that intestinal damage is a major determinant of cardiovascular out-
comes after MI [14]. Hence, early detection of remote intestinal injury
following cardiac I/R may help to estimate the risk of future cardio-
vascular events and therapeutic interventions targeting intestinal da-
mage may help to prevent the development of systemic inflammation.
Over the past decades, numerous treatment strategies have been
proposed to protect the heart against the detrimental effects of acute I/
R injury [1], but much less information is available on the impact of
these interventions on the remote effects of cardiac I/R, especially in
the intestines.
A possible pharmacological approach to reduce cardiac I/R injury-
induced inflammation is the inhibition of cyclooxygenase-2 (COX-2),
which is upregulated following permanent or transient myocardial
ischemia [15–17]. Although under some circumstances the increased
generation of COX-2-derived prostanoids may represent an adaptive
response that protects the cells from I/R injury [16,18], in the majority
of studies COX-2 inhibition decreased cardiac injury following perma-
nent or transient ischemia, pointing to a rather detrimental role of COX-
2 [17,19–23]. Our recent finding that chronic rofecoxib treatment re-
duced the infarct size in the myocardium after I/R concurs with these
studies, although we also demonstrated that its infarct size-limiting
effect was counterbalanced by higher mortality rate due to its pro-ar-
rhythmic property [24].
Rapid upregulation of COX-2 in response to local I/R has also been
demonstrated in the gastrointestinal tract [25,26], and COX-2 inhibi-
tion in most [26–28], though not all [29] studies reduced intestinal I/R
injury. In addition, there is some evidence that COX-2 inhibitors can
mitigate remote organ injury following limb or kidney I/R as well
[30–32]. It is, however, still not clear whether pharmacological
blockade of COX-2 confers any protection against remote intestinal
injury following cardiac I/R.
Another well-documented cardioprotective intervention is ischemic
preconditioning (IPC), in which the myocardium is subjected to brief
periods of ischemia prior to the induction of a prolonged ischemia in
order to initiate intrinsic cell-survival programs [33]. Although the
underlying mechanism is complex and still not fully understood, IPC
has been shown to target multiple factors involved in I/R injury such as
endothelial dysfunction, leukocyte activation and oxidative stress [34].
Of note, in our previous study cardiac IPC limited myocardial infarct
size to a comparable extent as rofecoxib treatment [24].
The tissue-protective effect of IPC has also been demonstrated in
other organs, including the gut [8,35]. Moreover, IPC of the organs
subjected to I/R may also provide protection against remote intestinal
damage [36]. However, it is not known whether IPC prior to cardiac I/R
can mitigate the remote damage of the gut.
Here we show for the first time the rapid development of histolo-
gical alterations and mild inflammation in the rat small intestine fol-
lowing cardiac I/R, and that two similarly effective infarct size-limiting
interventions, pharmacological blockade of COX-2 with rofecoxib and
IPC of the heart, have different impacts on them. Our study also iden-
tifies plasma MMP-2 activity as a potential biomarker for the detection
and estimation of cardiac I/R-induced early remote intestinal injury.
2. Materials and methods
2.1. Animals
Experiments were carried out on male Wistar rats weighing
180–280 g (Study I.) and 320–440 g (Study II.) (Semmelweis
University, Budapest, Hungary). Animals were housed in a temperature
(22 ± 2 °C)- and humidity-controlled room at a 12 h light/dark cycle.
Food and water were available ad libitum.
2.2. Materials
Rofecoxib [4-(4′ -methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]
was purchased from MedChem Express (Sollentuna, Sweden). All other
chemicals, unless otherwise stated, were obtained from Sigma-Aldrich
(St. Louis, MO, USA).
2.3. Ethical considerations
All efforts were made to minimize animal suffering and to reduce
the number of animals used in the experiments. All procedures con-
formed to the Directive 2010/63/EU on European Convention for the
protection of animals used for scientific purposes. The experiments
were approved by the National Scientific Ethical Committee on Animal
Experimentation and permitted by the government (Food Chain Safety
and Animal Health Directorate of the Government Office for Pest
County (PEI/001/1493-4/2015 and PE/EA/1784-7/2017)).
2.4. In vivo studies
2.4.1. Study I. Evaluating the impact of COX-2 inhibition and IPC on the
remote intestinal effects of cardiac I/R injury
In this study the same male Wistar rats were used as in our two
parallel studies focusing on the effects of long-term rofecoxib treatment
on myocardial ischemia/reperfusion injury [24] and on the composi-
tion of intestinal microbiota [37], which complies with the principles of
replacement, reduction and refinement of animal experiments [38]. In
the present study 7–11 rats were allocated to each treatment group.
Rats were treated intragastrically with either vehicle (1% hydro-
xyethylcellulose) or rofecoxib (5 mg/kg) in a volume of 0.33 ml/100 g
once daily for 28 days. The applied dose of rofecoxib was chosen partly
based on previous animal studies [39], based on the pharmacokinetic
similarities of rofecoxib in rats and humans [40] and extrapolation from
the maximal recommended daily dose (50 mg) used earlier in the
clinical practice, calculating with a 60-kg weight individual, according
to Reagan-Shaw et al. [41]. However, we have also confirmed the po-
tency of this rofecoxib dose and its selectivity for COX-2, as our results
showed that it inhibited COX-2-derived PGE2 synthesis by almost
100%, without having any effect on the gastrointestinal PGE2 levels
produced by COX-1 [37]. Of note, chronic rofecoxib treatment did not
increase the mortality of animals, and did not reduce the cardiac level
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of 6-keto prostaglandin F1α (the stable metabolite of prostacyclin),
which has been implicated in rofecoxib-induced cardiotoxicity [42]
(vehicle: 40.6 ± 6.3 pg/mg tissue, rofecoxib: 49.4 ± 7.3 pg/mg
tissue, n = 7/group, p = 0.38).
On the 29th day, i.e. 24 h after the final administration of rofecoxib,
all rats were anaesthetized with pentobarbital (60 mg/kg in-
traperitoneally) and underwent thoracotomy. Rats were ventilated with
rodent ventilator (Ugo-Basile, Gemonio, Italy) with 6.2 ml/kg tidal
volume at a rate of 69 ± 3 breath/min according to body weight. Their
blood pressure was continuously monitored in the carotid artery (AD
Instruments, Bella Vista, Australia), and their body temperature was
maintained at 37 °C with a heating pad. The right carotid artery was
cannulated for the measurement of mean arterial blood pressure (MAP,
AD Instruments, Bella Vista, Australia) and for fluid supplementation
with saline containing 10 IU/kg heparin. The time point of completing
all these procedures was designated as the starting point of experiment
(0 min). 40 min later, two groups of rats treated either with vehicle or
with rofecoxib, were subjected to sham operation, in which the left
anterior descending coronary artery (LAD) was isolated but not oc-
cluded (groups 1 and 3, VEH SHAM and ROF SHAM). In two other
groups (groups 2 and 4, VEH I/R and ROF I/R) cardiac I/R injury was
induced by occluding LAD for 30 min, followed by 120 min of re-
perfusion. In a further 5th group, IPC (3 cycles of 5 min LAD occlusion
followed by 5 min of reperfusion) was applied on vehicle-treated rats
directly before the 30 min LAD occlusion (VEH IPC + I/R).
Additionally, all animals received intraperitoneal injection of 100 IU/
kg heparin 3 times during the surgical procedure, at 35, 65 and
185 min. The study design and experimental protocol are illustrated in
Fig. 1. Although this design allowed us to analyze the effect of two
different infarct size-limiting interventions on cardiac I/R injury-
evoked intestinal responses parallel, for the sake of clarity the results
will be presented and discussed separately.
At the end of reperfusion, the rats were sacrificed, plasma samples
were collected and small intestines were excised. The mucosa of small
intestine was flushed with cold saline and photographed for subsequent
macroscopic analysis. Full-thickness pieces of the distal jejunum were
snap-frozen in liquid nitrogen and stored at −80 °C for further assays.
Other portions of intestinal tissues were fixed in 10% formalin for
histological analysis.
Intestinal tissue and plasma samples were collected only from ani-
mals surviving the whole protocol. Whereas all animals survived in
both VEH SHAM and ROF SHAM groups (n = 8/group), in the VEH-
treated I/R group 1 of the 7 animals died due to ventricular fibrillation
(14% mortality). Rofecoxib treatment following cardiac I/R was asso-
ciated with increased mortality rate, 4 of 9 animals died due to ar-
rhythmias (44%). In the VEH-IPC group (n = 11) 4 rats died during the
short I/R stimuli of IPC and were excluded from further evaluations,
and 1 of the remaining 7 animals died due to sudden drop in blood
pressure in the reperfusion period (14%).
In addition, hearts were excised in order to assess the infarct sizes.
These data were the subject of a separate paper [24], and herein we will
only refer to them.
2.4.2. Study II. Evaluating the effect of cardiac I/R injury with or without
IPC on the small intestinal microcirculation
This study was performed on a separate group of rats with weights
matching those of the vehicle-treated animals of Study I. at the day of
surgery (320–440 g). Animals were subjected to the same anaesthesia
and surgical procedure as before, but also median laparotomy was
performed and the distal jejunum of rats was gently exposed. Small
intestinal microcirculation was measured using a PeriScan PIM II laser
Doppler perfusion imager (Perimed, Stockholm, Sweden) placed 12 cm
above the surface of the jejunum. Each scanning was performed on an
area of 31 × 31 sampling points within 59 sec, followed by 1 sec pause.
Hence, imaging was performed in every minute, but we also aimed to
minimize the fluid and heat loss of animals and to avoid tissue de-
siccation [43]. Therefore, during the reperfusion period the opened
abdomen was repeatedly covered with saline-moistened gauze for
5 min intervals from the 95th to 180th min (i.e. from 95 to 100 min,
from 105 to 110 min, and so forth), and perfusion values for these
periods have not been recorded. Perfusion patterns were analyzed using
LDPIwin 2.6 software (Perimed, Stockholm, Sweden) and values were
Fig. 1. Experimental protocol. Male Wistar rats were treated with vehicle (VEH, 1% hydroxyethylcellulose) or rofecoxib (ROF, 5 mg/kg) for 28 days once daily (q.d.).
On the 29th day, rats were subjected to sham operation (groups 1 and 3, VEH SHAM and ROF SHAM) or cardiac ischemia (ISC) followed by reperfusion (groups 2 and
4, VEH I/R and ROF I/R). In an additional vehicle-treated group ischemic preconditioning (IPC) was applied (group 5, VEH IPC + I/R). Number of animals surviving
the whole protocol: 5–8/group. White arrow: intraperitoneal injection of 100 IU/kg heparin; black arrow: termination of animals and tissue sampling.
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expressed as percentage of the basal (pre-occlusion) values (registered
at 10 min).
2.5. Macroscopic evaluation of intestinal damage
High-resolution photographs of the entire small intestinal mucosa
were thoroughly analyzed and scored in blinded fashion, as follows: 0,
no visible morphologic alteration; 1, small (1–2 mm) hyperemic area at
one site; 2, small (1–2 mm) hyperemic areas at two or more sites; 3,
extensive (> 2 mm) hyperemic area at one site; 4, extensive (> 2 mm)
hyperemic areas at two or more sites [37].
2.6. Histological analysis
Samples taken from the distal part of the small intestine were fixed
in 10% formalin, embedded in paraffin, sectioned (5 µm), and stained
with haematoxylin and eosin. Digital micrographs were taken by an
Olympus BX51 microscope and Olympus DP50 camera. Histological
injury was assessed in blinded fashion by two histopathologists ac-
cording to the scoring system described by Mantyh et al [44] with
minor modifications (Table 1). The total histological score (ranging
from 0 to 9) was calculated based on the sum of partial scores.
2.7. Cytokine measurements
The jejunal levels of distinct cytokines were measured by either
Luminex xMAP technology, or ELISA. Excised and snap-frozen jejunal
tissues were pulverized and homogenized according to the manu-
facturers’ instructions. ELISA kit was used to quantify the protein levels
of tumor necrosis factor-α (TNF-α) (Invitrogen, Camarillo, CA, USA),
whereas Milliplex Multiplex assay to determine the levels of inter-
leukin-1β (IL-1β) and IL-10 by using customized Milliplex Rat Cytokin/
Chemokine Magnetic Bead Panel (Merck Millipore, Burlington, MA,
USA). The total protein concentration of samples was determined by
using a bicinchoninic acid assay kit (Thermo Scientific Pierce Protein
Research Products, Rockford, IL, USA) with bovine serum albumin
(BSA) as a standard, and cytokine amounts are given in pg/mg of total
protein.
2.8. Superoxide dismutase, catalase and malondialdehyde assays
The activities of superoxide dismutase (SOD) and catalase, as well as
the concentration of malondialdehyde (MDA) in the jejunum were
measured with assay kits according to the manufacturer's instructions
(Cayman Chemical, Ann Arbor, MI, USA).
The SOD kit utilizes a tetrazolium salt for the detection of super-
oxide radicals generated by xanthine oxidase and hypoxanthine, and
measures the activity of all three types of SOD (Cu/Zn, Mn and Fe-
SOD). One unit of SOD was defined as the amount of enzyme needed to
exhibit 50% dismutation of the superoxide radical. The total protein
concentration of supernatants was determined and SOD activity was
expressed in unit/mg protein.
The catalase kit utilizes the peroxidatic function of catalase for
determination of enzyme activity. The method is based on the reaction
of the enzyme with methanol in the presence of an optimal con-
centration of H2O2. The produced formaldehyde was measured spec-
trophotometrically with 4-amino-3-hydrazino-5-mercapto-1,2,4-tria-
zole as the chromogen. One unit of catalase was defined as the amount
of enzyme that causes the formation of 1 nmol of formaldehyde per
minute at 25 °C. Catalase activity was expressed in nmol/min/mg
tissue.
The measurement of jejunal MDA concentration was based on the
reaction of MDA with thiobarbituric acid, and the colorimetric quan-
tification of the formed adduct at 530 nm. Results were expressed as
nmol/mg tissue.Ta
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2.9. Immunohistochemistry
After routine FFPE specimen processing, deparaffinized sections
underwent antigen retrieval (pH = 6 citrate buffer, at 95 °C for
15 min). After blocking endogenous peroxidase activity (3% H2O2 so-
lution in PBS), the sections were blocked in appropriate sera (2.5% goat
serum in PBS). Then, sections were incubated with primary anti-ni-
trotyrosine antibody (06-284, 1:200, Merck Millipore, Burlington, MA,
USA) overnight in diluted blocking solution at 4 °C. After primary an-
tibody incubations, the sections were washed three times in PBS and
incubated for an hour with SignalStain® Boost IHC Detection Reagent
(HRP, Rabbit, 8114, Cell Signaling Technology, Danvers, MA, USA).
The secondary antibody was washed 3 times for 10 min and the specific
signal was developed with diaminobenzidine (ImmPACT DAB EqV
Peroxidase (HRP) Substrate, Vector Laboratories, Burlingame, CA,
USA). The specific staining was visualized and images were acquired
using a Leica DM3000 microscope (Leica, Wetzlar, Germany).
2.10. Measuring MMP-2 and MMP-9 activities by gelatin zymography
Activity of MMP-2 and MMP-9 was assessed by gelatin zymography
from plasma samples collected after 120 min of reperfusion.
Gelatinolytic activities of MMPs were examined as previously described
[45]. Briefly, 8% polyacrylamide gels were copolymerized with gelatin
(2 mg/ml, type A from porcine skin), and 50 µg of protein per lane was
loaded. An internal standard (American Type Culture Collection,
Manassas, Virginia) was loaded into each gel to normalize activities
between gels. After electrophoresis (90 V, 90 min), gels were washed
with zymogram renaturation buffer (Novex, Carlsbad, CA, USA) for
40 min. Samples were incubated for 20 h at 37 °C in zymogram de-
velopment buffer (Novex, Carlsbad, CA, USA).
In a separate experiment, one plasma sample from each group was
loaded into the gel in 4 replicates. After renaturation, the gel was cut
into 4 pieces, which were separately incubated in development buffer
containing vehicle or rofecoxib at 0.1, 1, or 10 μM concentrations, re-
spectively, in order to reveal whether rofecoxib has direct inhibitory
effect on MMP activity. The concentration of 1 µM was chosen for ro-
fecoxib based on the peak plasma concentration (Cmax) measured after a
single, 5 mg/kg oral dose of rofecoxib in rats [46].
Gels were then stained with 0.05% Coomassie brilliant blue in a
mixture of methanol-acetic acid-water [2.5:1:6.5 (v/v)] and destained
in aqueous 4% methanol-8% acetic acid (v/v) to remove aspecific
binding of Coomassie. For positive controls, gelatinase zymography
standard containing human MMP-2 and MMP-9 (Chemicon Europe Ltd.,
Southampton, UK) was used. For negative control, lanes containing
tissue samples were cut off after renaturation of the gel and were se-
parately incubated for 20 h at 37 °C in development buffer in the pre-
sence of the calcium chelator EGTA (ethylene glycol-bis(2-aminoethy-
lether)-N,N,N′,N′-tetraacetic acid; 10 mM). Gelatinolytic activities were
detected as transparent bands against the dark-blue background. Gels
were scanned in a transilluminator and band intensities were quantified
by Quantity One software (BioRad, Hercules, CA, USA), and expressed
as the ratio to the internal standard, and presented in arbitrary units.
2.11. Western blot measurements
Distal jejunal tissues were homogenized with a TissueLyser (Qiagen,
Venlo, The Netherlands) in lysis buffer containing 200 mM NaCl, 5 mM
EDTA, 10 mM Tris, 10% glycerine, and 1 µg/ml leupeptin (pH 7.4),
supplemented with a protease inhibitor cocktail (cOmplete ULTRA
Tablets, Roche, Basel, Switzerland) and PMSF (Sigma, St. Louis, MO,
USA). The homogenized lysates were centrifuged twice at 1,500 × g
and 4 °C for 15 min, then the supernatants were collected and their
protein concentration was measured by the bicinchoninic acid assay
(Thermo Fisher Scientific, Waltham, MA, USA). Equal amount of pro-
tein (20 µg) was mixed with Pierce Lane Marker reducing sample buffer
(Thermo Fisher Scientific, Waltham, MA, USA), and loaded and sepa-
rated in a 4–20% precast Tris-glycine SDS polyacrilamide gel (BioRad,
Hercules, CA, USA). Proteins were transferred electrophoretically onto
a polyvinylidene difluoride membrane (BioRad, Hercules, CA, USA) at
200 mA overnight. Membranes were blocked with 5% nonfat dry milk
(BioRad, Hercules, CA, USA) in Tris-buffered saline containing 0.05%
Tween-20 (0.05% TBS-T; Sigma, St. Louis, MO, USA) at room tem-
perature for 2 h. Membranes were incubated with primary antibodies
against COX-2 (12282, 1:500) and COX-1 (4841, 1:500) (Cell Signaling
Technology, Danvers, MA, USA) overnight at 4 °C, followed by 2 h
incubation at room temperature with anti-rabbit HRP-linked secondary
antibody. GAPDH was used to control for sample loading and protein
transfer and to normalize the content of target protein. Signals were
detected with a chemiluminescence kit (BioRad, Hercules, CA, USA) by
Chemidoc XRS+ (BioRad, Hercules, CA, USA).
2.12. Evaluation of 6-keto prostaglandin F1α
Tissue levels of 6-keto prostaglandin F1α were determined by ELISA,
according to the manufacturer's instructions (Cayman Chemical, Ann
Arbor, MI, USA). Briefly, tissues were homogenized in precooled
acetone containing 10 µM indomethacin, and centrifuged at 10,000 g
for 10 min at 4 °C. Acetone was evaporated from the supernatants using
a vacuum centrifuge, then the residues were resolved in assay buffer
and used for determination of 6-keto prostaglandin F1α.
2.13. Statistics
Data are expressed as mean ± SEM. Statistical analysis of the data
was performed with one-way or two-way ANOVA, or in case of non-
parametric values with Mann-Whitney (pairwise comparison) or
Kruskal-Wallis tests. Two-way repeated measures ANOVA was used to
compare the time course of blood pressure and jejunal blood flow
changes. Correlations between MMP-values and histological scores
were calculated by Spearman test. Outliers detected by Grubb’s test
were excluded from the analyses. In the in vitro assays all samples were
measured at least in duplicates, and most measurements were repeated
two times. In all cases, a probability of p < 0.05 was considered sta-
tistically significant.
3. Results
3.1. Cardiac I/R induced early histological alterations in the small intestine
of vehicle-but not rofecoxib-treated rats
Occlusion of LAD for 30 min, followed by 2 h reperfusion did not
cause any appreciable macroscopic alteration in the small intestine of
vehicle- or rofecoxib-treated rats (Fig. 2A). By contrast, histological
analysis revealed early significant alterations in the jejunal mucosa of
vehicle-treated rats subjected to cardiac I/R compared to sham-oper-
ated controls. This was mainly characterized by subepithelial edema
with dilated vessels containing numerous red blood cells, and was ob-
served in almost all animals (in 5 of 6 rats). In addition, in half of the I/
R animals increased number of leukocytes (lymphocytes, macrophages
and granulocytes) could be detected in the lamina propria, including
extravasated ones, indicating an increase in vascular permeability. The
epithelium and structure of villi were generally preserved, although
early signs of epithelial distruption at the tips of some villi were also
found in 5 of 6 animals. Altogether, the overall histological score was
significantly higher in the I/R group compared to the sham-operated
group. Such morphological changes, however, were not observed in the
I/R group treated with rofecoxib, indicating that inhibition of COX-2
prevented remote intestinal injury after cardiac I/R (Fig. 2B and 2C).
As we reported before, chronic rofecoxib treatment also reduced the
myocardial infarct size after cardiac I/R in these animals, at least partly
due to a direct cardio-cytoprotective effect, but it also increased acute
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mortality by increasing the incidence of arrhythmias (see section 2.4
and Ref. [24]).
3.2. Rofecoxib treatment inhibited the development of mild intestinal
inflammation following cardiac I/R injury
Because histological analysis suggested the presence of mild in-
testinal inflammation in the vehicle-treated I/R group, in the next step
we aimed to characterize it by measuring different inflammatory factors
known to be involved in I/R injury. First, we assessed the intestinal
level of COX-2, because its upregulation is an early response to I/R. In
contrast to sham-operated animals with barely detectable COX-2 ex-
pression, vehicle-treated rats following cardiac I/R exhibited sig-
nificantly higher COX-2 protein levels in the jejunum. By contrast, in
ROF-treated animals cardiac I/R did not increase the intestinal ex-
pression of COX-2, compared to that of the respective sham group
(Fig. 3A). The protein levels of the constitutive COX-1 isoform, in
contrast to those of COX-2, were similar in all groups irrespective of
treatment (Fig. 3B).
The expression of COX-2 can be induced by various pro-in-
flammatory cytokines such as TNF-α and IL-1β [47]. These cytokines,
especially TNF-α, also play an important role in the orchestration of
inflammatory response to I/R in most tissues [2]. We found, however,
no differences in terms of intestinal TNF-α levels between the groups,
and IL-1β even showed a mild reduction in the rofecoxib-treated I/R
group compared to the respective sham group (Fig. 3C, 3D).
We also measured the tissue levels of the anti-inflammatory IL-10,
because this cytokine is known to be produced in acute inflammation by
numerous cells parallel with pro-inflammatory cytokines in order to
regulate immune responses [48]. As Fig. 3E shows, there were only
moderate differences in IL-10 levels, although those reflected somewhat
the changes in histological scores and COX-2 levels. Namely, the
highest concentration of IL-10 was measured in the vehicle-treated I/R
group, whereas significantly lower levels were detected in rofecoxib-
treated animals subjected to I/R.
Similarly, the highest level of 6-keto prostaglandin F1α (the stable
metabolite of prostacyclin, which is mainly produced by COX-2 in in-
flammation [49]) was measured in the vehicle-treated I/R group
(Fig. 3F), but the differences between the groups did not reach statis-
tical significance.
Finally, because oxidative stress and RONS are well-established
factors in the pathogenesis of I/R injury, we aimed to determine the
tissue activities of SOD and catalase, two first line antioxidant enzymes
involved in removal of toxic oxygen metabolites and preventing cellular
damage [50]. Whereas catalase activities were similar in all groups,
total SOD activity tended to rise in the vehicle-treated I/R group, and
increased significantly in rofecoxib-treated I/R animals (Fig. 4A and
4B). Superoxide anion, besides nitric oxide, is one of the initial RONS
Fig. 2. The effects of 4-week treatment with vehicle (VEH) and rofecoxib (ROF, 5 mg/kg) on macroscopic (A) and histological scores (B) of jejunum. Data are
expressed as mean ± SEM. For pairwise comparison of respective treatment groups Mann-Whitney test was used, n = 5–8/group (*P < 0.05 vs. respective VEH,
#P < 0.05 vs. respective SHAM). Panel C demonstrates representative histological micrographs (scale bar: 100 µM, haematoxylin and eosin staining). Cardiac
ischemia/reperfusion (I/R) injury induced histological alterations in vehicle-treated (VEH) rats. White arrows demonstrate dilated capillaries with numerous red
blood cells in the lumen, whereas increased cellularity of the lamina propria with increased number of granulocytes, including extravasated ones is marked by
asterisk. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 3. Jejunal levels of cyclooxygenase-2 (COX-2, A), COX-1 (B), tumor necrosis factor-α (TNF-α, C), interleukin-1β (IL-1β, D), IL-10 (E) and 6-keto prostaglandin
F1α (6-keto PGF1α, F) in rats treated with vehicle (VEH) or rofecoxib (ROF, 5 mg/kg) for 4 weeks and subjected to sham operation or cardiac I/R injury. Results are
expressed as mean ± SEM. For statistical analysis two-way ANOVA was used, followed by Fisher’s LSD post hoc test, n = 5–8/group (*P < 0.05 vs. respective VEH,
#P < 0.05 vs. respective SHAM).
Fig. 4. Jejunal activities of the antioxidant superoxide dismutase (SOD, A) and catalase (B), and the tissue levels of malondialdehyde (MDA, C) in rats treated with
vehicle (VEH) or rofecoxib (ROF, 5 mg/kg) for 4 weeks and subjected to sham operation or cardiac I/R injury. Results are expressed as mean ± SEM. For statistical
analysis two-way ANOVA was used, followed by Fisher’s LSD post hoc test, n = 5–8/group (*P < 0.05 vs. respective VEH, ##P < 0.01 vs. respective SHAM). Panel
D: immunohistochemistry for nitrotyrosine, showing weak and sparse staining (arrows). Scale bar: 50 µM.
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generated during I/R [51] and SOD catalyzes its dismutation into hy-
drogen peroxide and molecular oxygen. Hence, increased SOD activity
in rofecoxib-treated animals may reflect an enhanced defensive re-
sponse to elevated intracellular superoxide level [52]. Nevertheless, the
level of intestinal MDA (a marker of lipid peroxidation) showed no
major difference among the treatment groups (Fig. 4C). We also as-
sessed the extent of protein tyrosine nitration (a marker of nitrosative
stress), but as Fig. 4D demonstrates, nitrotyrosine staining showed only
a weak and sparse signal even in the I/R groups (Fig. 4D).
Collectively, these data indicate that 2 h of reperfusion following
cardiac ischemia induced only mild responses in the small intestine, but
those were prevented by rofecoxib treatment.
3.3. The activity of MMP-2 but not MMP-9 in the plasma correlated with
the intestinal histological score
The pivotal role of certain types of MMPs, especially MMP-2 and
MMP-9, in I/R injury has been demonstrated in numerous organs in-
cluding the heart [4,5] and gastrointestinal tract [53]. Moreover, there
is evidence that both types are involved in remote I/R injury as well [6].
Therefore, in the next step we aimed to determine the activities of
MMP-2 and MMP-9, the most abundant MMP types in the myocardium,
from plasma samples with gelatin zymography. By gelatin zymography,
two distinct bands were detected for both MMP-2 (72 and 75 kDa) and
MMP-9 (86 and 92 kDa) (Fig. 5I), representing different zymogen and
active forms [45]. Analysis of band intensities revealed that cardiac I/R
increased the plasma activity of both MMP-2 isoforms in the vehicle-
treated group, which was attenuated by rofecoxib treatment (Fig. 5A
and 5B). In addition, plasma MMP-2 activities showed a relatively
weak, but statistically significant positive correlation with the
histological scores of intestines (Fig. 5E and 5F).
By contrast, although plasma MMP-9 activities showed similar
trends, they neither differed between the groups significantly (Fig. 5C
and 5D), nor correlated with the histological scores (Fig. 5G and 5H).
These results suggest that increased activity of MMP-2, but not
MMP-9 in the circulation is associated with early intestinal injury fol-
lowing cardiac I/R, and the protective effect of rofecoxib is associated
with lower MMP-2 activity.
3.4. Rofecoxib did not inhibit the activity of MMP-2 and MMP-9 in vitro
In order to assess whether lower MMP-2 activity in the rofecoxib-
treated I/R group is due to direct inhibition of MMP-2 activity by ro-
fecoxib or due to reduced protein expression, gelatinolytic activities of
plasma samples from each group were examined in gels incubated with
different concentrations of rofecoxib.
As Fig. 6 shows, none of the tested rofecoxib concentrations in-
hibited the activity of either MMP isoforms in vitro, suggesting that
lower plasma MMP-2 activities of rofecoxib-treated I/R rats are the
result of decreased enzyme synthesis.
3.5. Ischemic preconditioning of the myocardium failed to ameliorate the
remote intestinal damage following cardiac I/R
We aimed to examine the influence of IPC, another infarct size-
limiting intervention, on cardiac I/R injury-evoked intestinal responses
as well. For this purpose, all above-mentioned measurements were also
performed on intestinal and plasma samples of vehicle-treated rats
subjected to 3 cycles of 5 min LAD occlusion followed by 5 min of
reperfusion, prior to the prolonged ischemia and reperfusion. This IPC
Fig. 5. Panels A-D: Gelatinolytic activities of matrix metalloproteinase-2 (MMP-2, 72 kDa, A; 75 kDa, B) and MMP-9 (86 kDa, C; 92 kDa, D) in plasma samples of
animals treated with vehicle (VEH) or rofecoxib (ROF, 5 mg/kg) for 4 weeks and subjected to sham operation or cardiac I/R injury. Results are expressed as
mean ± SEM. For statistical analysis two-way ANOVA was used, followed by Fisher’s LSD post hoc test, n = 4–5/group (*P < 0.05 and ***P < 0.001 vs.
respective VEH, ##P < 0.01 vs. respective SHAM). Panels E-H: Correlations between MMP-2 and MMP-9 activities and histological scores of rats in the VEH SHAM
(empty black circles), VEH I/R (grey filled black circles), ROF SHAM (empty red circles) and ROF I/R (grey filled red circles) groups, calculated by Spearman test.
Panel I: Representative zymograms of plasma matrix metalloproteinase-2 (MMP-2) (72 and 75 kDa) and MMP-9 activities (86 and 92 kDa) in vehicle- (VEH, 1%
hydroxyethylcellulose) and rofecoxib-treated (ROF, 5 mg/kg) rats subjected to sham operation or cardiac ischemia/reperfusion injury (I/R). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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protocol has afforded reliable cardioprotection in our previous works,
and also reduced the myocardial infarct size significantly in the present
animals [24].
However, as Fig. 7 shows, IPC of the myocardium failed to inhibit
the development of mild intestinal damage and inflammation after
cardiac I/R. Namely, histological score and COX-2 protein expression in
the IPC + I/R group were significantly elevated and were comparable
to those of the I/R group (Fig. 7A and 7B). All other measured para-
meters that were unaffected by cardiac I/R (7C-7G) (including macro-
scopic scores, IL-1β concentrations and catalase activities, which are
not shown), remained unaltered in the IPC + I/R group as well.
Cardiac IPC had no effect on the cardiac I/R-evoked elevation of
plasma MMP-2 activities either. As Fig. 8 demonstrates, plasma activ-
ities of both MMP-2 isoforms were significantly higher in the IPC + I/R
group than in sham-operated animals (Fig. 8A and 8B). When the MMP-
2 activities of all vehicle-treated animals irrespective of surgical pro-
cedure were correlated to the respective histological scores, a strong
correlation between the two parameters was detected (Fig. 8E and 8F).
By contrast, in terms of MMP-9 activities we found no significant dif-
ferences between the groups (Fig. 8C and 8D), and MMP-9 activities
showed no correlation with the histological scores (Fig. 8G and 8H).
3.6. IPC prevented the transient jejunal hypoperfusion caused by cardiac I/
R
We addressed the question whether the inability of the applied
cardioprotective IPC to prevent cardiac I/R-evoked intestinal damage is
due to impaired intestinal microcirculation during the multiple is-
chemic periods. Therefore, in a separate study jejunal microcirculation
was assessed by laser Doppler perfusion imaging in weight-matched
rats and systemic blood pressure was measured in parallel.
In sham-operated animals both the mean arterial blood pressure and
jejunal blood flow remained stable during the entire observation period
(Fig. 9). 30 min LAD occlusion without IPC induced prompt reduction
in the blood pressure, partly due to transient arrhythmias, which was
accompanied by impaired jejunal microcirculation. The latter, how-
ever, proved to be moderate (15.5% reduction on average, peaking at
31.6%) and transient, and microcirculation was normalized within
15 min, whereas the systemic blood pressure of animals failed to re-
cover completely and remained lower until the end of experiment. On
the other hand, brief LAD occlusions during IPC resulted in mild, mostly
non-significant reductions in the systemic blood pressure, and atte-
nuated the blood pressure changes in response to prolonged I/R. More
Fig. 6. The effects of different concentrations of rofecoxib (ROF, 0.1, 1 and 10 µM) in vitro on the gelatinolytic activities of matrix metalloproteinase-2 (MMP-2
72 kDa, A; 75 kDa, B) and MMP-9 (86 kDa, C; 92 kDa, D). Data are expressed as mean ± SEM. For statistical analysis one-way ANOVA was used, followed by Fisher’s
LSD post hoc test, n = 5/group.
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importantly, IPC completely prevented the transient drop in jejunal
microcirculation during the 30 min LAD occlusion, and blood flow re-
mained stable during the whole experiment.
Our findings that cardiac I/R caused only mild and temporary in-
testinal microcirculatory impairment which was completely prevented
by IPC suggest that the histological damage of intestine in the I/R and
IPC + I/R groups was not likely due to intestinal ischemia.
4. Discussion
Here we demonstrate for the first time the presence of overt histo-
pathological alterations in the rat small intestine as early as 2 h
Fig. 7. Intestinal histological scores (A), jejunal tissue levels of cyclooxygenase-2 (COX-2, B), COX-1 (C), tumor necrosis factor-α (TNF-α, D) and 6-keto prostaglandin
F1α (6-keto PGF1α, E), tissue activity superoxide dismutase (SOD, F), and concentration of malondialdehyde (MDA, G) in vehicle-treated rats subjected to sham
operation and cardiac ischemia/reperfusion injury (I/R) with or without cardiac ischemic preconditioning (IPC). Data are expressed as mean ± SEM. Statistical
analysis was performed with Kruskal-Wallis test followed by Dunn’s post hoc test (A), and one-way ANOVA followed by Fisher’s LSD post hoc test (B-G), n = 6–8/
group (#P < 0.05 vs. SHAM).
Fig. 8. Panels A-D: Gelatinolytic activities of matrix metalloproteinase-2 (MMP-2, 72 kDa, A; 75 kDa, B) and MMP-9 (86 kDa, C; 92 kDa, D) in plasma samples of
vehicle-treated rats subjected to sham operation or cardiac ischemia/reperfusion injury (I/R) with or without cardiac ischemic preconditioning (IPC). Results are
expressed as mean ± SEM. For statistical analysis one-way ANOVA was used, followed by Fisher’s LSD post hoc test, n = 4–5/group (#P < 0.05 and ##P < 0.01
vs. SHAM). Panels E-H: Correlations between MMP-2 and MMP-9 activities and histological scores of rats in the VEH SHAM (empty black circles), VEH I/R (grey
filled black circles) and VEH IPC (black filled circles) groups, calculated by Spearman test. Panel I: Representative zymograms of plasma matrix metalloproteinase-2
(MMP-2) (72 and 75 kDa) and MMP-9 activities (86 and 92 kDa) in vehicle-treated (VEH, 1% hydroxyethylcellulose) rats subjected to sham operation, cardiac
ischemia/reperfusion injury (I/R), or cardiac ischemic preconditioning (IPC) followed by I/R (IPC + I/R).
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following reperfusion of the ischemic myocardium, which show posi-
tive correlation with circulatory MMP-2 activity. Our results also sug-
gest that different pharmacological or surgical strategies aiming to re-
duce the extent of cardiac I/R injury do not necessarily provide
protection against remote I/R injury arising in distant organs. Namely,
two infart size-limiting interventions, pharmacological blockade of
COX-2 with rofecoxib and cardiac IPC, had different effects on remote
gut injury as only the former intervention was able to prevent it.
The intestine is particularly sensitive to I/R injury [8]. A few recent
studies have demonstrated that remote intestinal injury can occur also
in response to permanent or transient coronary artery ligation in rats
and mice [13,14,54] and in MI patients [14]. Moreover, gut injury may
predispose patients to adverse cardiovascular events post-MI [14],
suggesting that early detection and prevention of remote intestinal
damage following cardiac I/R is of outmost clinical importance. In these
studies, based on the time points of analysis and detection of mor-
phological and functional alterations, the appearance of intestinal in-
jury was expected in the range of days to weeks. Our results indicate the
presence of intestinal damage already 2 h after reperfusion of the is-
chemic myocardium, suggesting that gut injury develops much more
rapidly, similarly to that after I/R of the limbs [9,10] or the kidney
[11].
The remote injury of the intestine in this early phase was char-
acterized mainly by histological alterations including mild subepithelial
edema and increased vascular permeability, which are early signs of
ischemic injury [55]. These changes were accompanied by significant
elevation of COX-2 protein expression in the jejunum, which again is an
early response to I/R in numerous organs [16,25,56] including the
small intestine [26,27], and occurs in tissues remote to the initial site of
injury as well [32,57]. COX-2 and its products thereafter may induce
either pro-inflammatory [26,32] or cytoprotective effects [16,25] de-
pending on the involved cell types and on the intensity of COX-2 in-
duction. Whether upregulation of intestinal COX-2 in the present study
confers protection or is rather detrimental and aggravates tissue injury
remains to be established. Although long-term treatment with rofecoxib
mitigated the intestinal damage after cardiac I/R, our results also in-
dicate that COX-2 expression in these intestines remained low. Hence,
as discussed below, the protective effect of rofecoxib was not likely due
to inhibition of COX-2 at the level of intestine, but was rather initiated
at a remote site.
Despite the histological signs of tissue injury the jejunal con-
centrations of cytokines and oxidative stress markers showed no or only
minor differences in response to cardiac I/R. These results suggest that
our cardiac I/R injury model induced only mild intestinal damage being
insufficient to trigger significant cytokine elevation or oxidative da-
mage, in contrast to other remote intestinal I/R injury models with si-
milar durations of reperfusion (1–5 h) [11,58]. Of note, in a recent
study 6-min of cardiac arrest followed by cardio-pulmonary resuscita-
tion in rats induced histological damage of the jejunum within 6 h,
whereas the tissue levels of cytokines increased only after 24 h [59].
Thus, the severity and onset of intestinal inflammation may depend
largely on the applied I/R model and histological analysis may reveal
mild alterations prior to significant changes of cytokines.
To date, numerous circulating factors have been implicated in the
Fig. 9. The effects of SHAM operation and oc-
clusion of left anterior descending coronary ar-
tery (LAD) for 30 min followed by 120 min of
reperfusion, with or without cardiac ischemic
preconditioning (IPC), on the mean arterial
pressure (MAP, A) and jejunal blood flow (B).
Results are expressed as percentages of the pre-
occlusion values registered at 10 min. Circles
and error bars represent mean + SEM. n = 6–9/
group, for statistical analysis two-way repeated
measures ANOVA was used, followed by Holm-
Sidak post hoc test. Filled circles represent
P < 0.05 vs. respective SHAM values,
whereas + denotes P < 0.05 between re-
spective I/R and IPC + I/R values.
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pathogenesis of remote organ injury after I/R injury [60,61]. Our pre-
sent data indicate that MMP-2 might be one of them, as its plasma
activity showed positive correlation with remote intestinal injury after
cardiac I/R. This finding is in accordance with previous studies showing
that MMP-2 and MMP-9 are involved in remote lung injury after I/R of
the limbs [6,7]. However, we found no significant correlation between
the gelatinolytic activities of plasma MMP-9 and intestinal histological
scores, which implies that only specific types of MMPs play roles in the
development of intestinal injury after cardiac I/R, at least under the
present experimental circumstances.
We extended our work to analyze the jejunal blood flow by laser
Doppler imaging. Our data revealed that in our model the impairment
of local microcirculation is not likely to be involved in the development
of remote intestinal damage either. Namely, cardiac I/R induced only
moderate (30%) and temporary reduction in jejunal blood flow, and
there is evidence that small intestine can sustain even prolonged per-
iods of ischemia (2 h) without injury, as long as blood flow is reduced to
levels (> 50% of control) that do not substantially decrease oxygen
consumption [55]. Furthermore, cardiac IPC attenuated the changes in
blood pressure and prevented completely the reduction in jejunal blood
flow after cardiac I/R, but failed to ameliorate intestinal injury, as
discussed below.
Another main finding of the present study is that two different in-
farct size-limiting interventions had diverging effects on the intestine,
suggesting that infarct size reduction per se does not automatically
translate to remote organ protection, and different therapeutic inter-
ventions aiming to limit cardiac injury in MI patients may have sub-
stantially different outcomes in distant organs.
Our finding that rofecoxib reduces cardiac I/R injury is in agree-
ment with previous studies showing that different COX-2 inhibitors
exert cardioprotection following permanent or transient myocardial
ischemia [17,20–23]. Needless to say, the infarct size-reducing property
of rofecoxib has only limited clinical relevance, as this compound was
withdrawn from the market due to serious adverse cardiovascular ef-
fects observed in the VIGOR and APPROVe trials [62,63]. In fact, our
cardiac I/R model also revealed the hidden cardiotoxic, pro-arrhythmic
properties of rofecoxib [24]. Nevertheless, it proved to be a valuable
test compound to analyze the remote intestinal effects of myocardial
protection after cardiac I/R.
The infarct size-limiting effect of rofecoxib was accompanied by
significant reduction in intestinal injury. Rofecoxib treatment also
prevented the rise of jejunal COX-2 expression in response to cardiac I/
R, therefore it is unlikely that the observed protective effect of rofecoxib
was primarily due to inhibition of COX-2 activity at the level of intes-
tine. Instead, it may be rather due to modulating the release and/or
activity of different circulatory factors that induce remote tissue injury.
This assumption is supported by the finding that rofecoxib prevented
the elevation of plasma MMP-2 activity in response to cardiac I/R, and
the decrease in MMP-2 activity correlated with the reduction in in-
testinal histological score. The low circulatory MMP-2 activity in rofe-
coxib-treated I/R animals is likely due to an inhibition of MMP-2 re-
lease or synthesis, and not due to direct inhibition of MMP-2 activity,
since rofecoxib at concentrations comparable to those measured in the
rat plasma after 5 mg/kg oral dose [46] did not inhibit the gelatinolytic
activity of MMP-2 in vitro. Our finding is corroborated by previous re-
ports showing that COX-2 and prostaglandin E2 upregulate MMP-2
expression in tumor cells and atherosclerotic lesions, and pharmacolo-
gical inhibition of COX-2 with different compounds including rofecoxib
suppresses MMP-2 activity via the inhibition of MMP-2 gene tran-
scription [64–66].
The inability of cardiac IPC to mitigate remote intestinal injury
despite its robust cardioprotective effect is an issue that remains to be
resolved. The lack of protection in the intestine is likely due to the high
activity of plasma MMP-2 in the circulation, which, in contrast to ro-
fecoxib, was not influenced by IPC and showed strong positive corre-
lation with the severity of histological damage. It is well-established
that reperfusion of the ischemic myocardium increases MMP-2 activity
in the coronary effluent in vitro [4] and in plasma in vivo within minutes
[67]. In addition, our previous studies have consistently demonstrated
that the same IPC protocol used in the present experiment prevented
the early release of MMP-2 from the isolated heart, preserved cardiac
mechanical function and limited infarct size [68], indicating that in-
hibition of early MMP-2 activation is an effector mechanism in IPC-
evoked cardioprotection. However, to our best knowledge, there is no
available data on the effect of cardiac IPC in vivo on the time-course of
plasma MMP-2 activity. Our present study indicates that IPC had no
effect on plasma MMP-2 activity at a single time point, after 2 h of
reperfusion, but this does not allow us to draw any conclusions on the
effects of IPC in the first minutes of reperfusion. Moreover, it is also
plausible that plasma MMP-2 activity at this later time point originates
from the release of MMP-2 from multiple organs as a result of remote
organ injury [6], which conceals the inhibitory effect IPC on the cardiac
release of MMP-2. Nevertheless, our experiment clearly demonstrates
that plasma MMP-2 activities measured at certain time points after
cardioprotective interventions may not correlate with cardiac injury,
and that IPC-evoked cardioprotection may involve mechanisms in-
dependent of MMP-2 inhibition.
Finally, it should be noted that our study also has some limitations.
First, the use of rofecoxib instead of other clinically available selective
COX-2 inhibitors has certainly limited translational relevance.
Nevertheless, as this compound has a high pKa value (in contrast to
etoricoxib, which therefore can trigger topical damage [69]) and lacks
any direct antibacterial effects (in contrast to celecoxib) [37], it proved
to be a useful tool for analysing the impact of COX-2 inhibition on
cardiac I/R-induced bowel damage, without having any above-men-
tioned, non-COX-2-dependent intestinal effects. Second, only male rats
were used in the present study, despite that numerous studies reported
gender differences in I/R injury [70,71]. Hence, although the infarct
size-limiting and intestinoprotective effects of COX-2 inhibition and IPC
have been reported in both genders [21,27,72,73], it remains to be
established whether our results can be translated to females. Third, the
present study focused only on the analysis of intestinal effects evoked
by cardiac I/R injury, and the cardiac effects of rofecoxib and IPC were
not investigated. Therefore, at present we cannot explain why the ef-
fects of two infarct size-limiting interventions on the plasma MMP ac-
tivities and intestinal integrity are different, and careful parallel ana-
lysis of both the cardiac and intestinal tissues will be required to
decipher it. In addition, further studies will be required to assess the
effects of COX-2 inhibition and IPC at another, later time points fol-
lowing cardiac I/R, as the short reperfusion period applied in the pre-
sent study induced only very mild intestinal responses. Finally, at
present the potential role of MMP-2 in the pathogenesis cardiac I/R
injury-induced intestinal damage is based only on correlation analysis,
and further experiments are required to determine whether MMP-2
contributes to the observed damage.
In conclusion, to our best knowledge this is the first demonstration
of early histological alterations and mild inflammation in the rat small
intestine 2 h after cardiac I/R injury. These changes were associated
with increased activity of MMP-2, but not MMP-9 in the circulation,
suggesting that plasma MMP-2 activity is a potential biomarker for the
detection and estimation of cardiac I/R-induced early gut damage. Two
infarct size-limiting interventions, pharmacological blockade of COX-2
by rofecoxib and cardiac IPC, had different effects on the development
of remote intestinal injury, as only rofecoxib treatment was able to
prevent it. The protective effect of rofecoxib may at least partly rely
upon its ability to prevent the rise of MMP-2 activity in the circulation
after cardiac I/R. Our study highlights the importance of evaluating the
local and systemic effects of cardiac I/R injury in parallel, because
different infarct size-limiting interventions may have substantially dif-
ferent impacts on remote organs.
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